Iryna Ethell, PhD, at University of California

Role of Matrix Metalloproteinases (MMP-9) in Fragile X

February 2, 2009

With a $220,000 grant from FRAXA Research Foundation over 3 years, Dr. Iryna Ethell from the University of California at Riverside studied the regulation of dendritic structure by matrix metalloproteinases and other extracellular signaling pathways. This work identified a major treatment strategy for Fragile X with the available MMP-9 inhibitor, minocycline.

Read More »

3 Researchers Honored at FRAXA Investigators Meeting

October 4, 2008

Over 150 scientists from around the world gathered at FRAXA’s 2008 Investigators Meeting to share discoveries and speed treatments for Fragile X syndrome.

Read More »
Iryna Ethell, PhD, at University of California

Researchers Propose Minocycline to Treat Fragile X

October 4, 2008

This team has found that an available drug called minocycline, an inhibitor of mmp9, might also be used to treat Fragile X. Clinical trials later tested this.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)